Address: Energieweg 1, 3641 RT, Mijdrecht,Netherlands
Tel: +31 297 28 06 66
Web: http://www.bayer.nl/ebbsc/cms/nl/index.html
Bayer’s presence in the Netherlands segments Bayer HealthCare, Bayer CropScience and Bayer MaterialScience. The main markets for Bayer products in the Netherlands are health, agriculture, construction and automotive industries. The three segments in our land will yield about 500 million euros in turnover of the parent group and employs around 600 people.
Bayer HealthCare’s aim is to human and animal health promotion. With innovative products, we are improving the welfare and quality of life by diagnosing, preventing and treating diseases.
Bayer HealthCare comprises four divisions. Bayer Shering Pharma, Animal Health, Consumer Care and Diabetes Care. There are more than 53,400 people work for Bayer HealthCare.
The business units of the division Bayer Schering Pharma – General Medicine, Specialized Therapeutics, Hematology / Oncology, Diagnostic Imaging – have medicines to treat diseases such as cancer, cardiovascular diseases, infections, immune and metabolic disorders, multiple sclerosis. There are also funds for contraception, erectile problems and products for imaging (contrast media).
Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall…
Roche Netherlands General Manager Bart Vanhauwere explains how the company has managed to foster growth at the Dutch affiliate thanks to its long-term strategic vision and the collaborative approach it…
Europe’s longest-standing Minister of Health, Edith Schippers, provides insight into the local healthcare system and continued efforts to improve quality of life for Dutch citizens, as well as revealing the…
Sean Connor, General Manager Benelux and UK/ROI for ALK, details the company’s strategy both in terms of products and therapeutic areas and provides us with his assessment of Netherlands regulatory…
A well-established player in the Allergy market, the Dutch company HAL Allergy recently expanded its activities with the addition of its HALIX Contract Manufacturing Outsourcing (CMO) arm. CEO Harry Flore…
With almost thirty years of experience in the life sciences sector, local Dutch consultancy firm Baggerman Farma Consult offers a wide portfolio of services to its clients in the pharmaceutical…
Professor Paul Smits, Dean and Vice Chairman of Radboud University Medical Center in the Netherlands, shares his insights into the strengths of the country’s research climate and the challenges posed…
John Verhoeven, Partner and co-founder of Eagle Rock Life Sciences, a Dutch independent consultancy offering a broad range of services to both Dutch and international life sciences companies, explains how…
As Director of the Netherlands’ association for innovative medicines, Gerard Schouw outlines new strategies to enhance the Dutch research climate; foster greater collaboration between all stakeholders and improve public perception…
Manfred Rüdiger (MR), Robbert Van Heekeren (RVH) and Jeroen Rovers (JR), respectively CEO, CFO and CMO of Kiadis Pharma, a Dutch biopharmaceutical company focused on cell-based immunotherapy products for the…
After a successful IPO on Nasdaq in May 2015, Galapagos is ready to continue developing its robust portfolio of clinical-stage breakthrough therapies with the potential to revolutionize existing treatment paradigms.…
The future of drug development is about interacting, sharing and collaborating. The President and CEO of Genmab, an international biotechnology company focusing on differentiated antibody therapeutics for the treatment of…
See our Cookie Privacy Policy Here
